No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
XOMA XOMA Corp
- 25.410
- +0.050+0.20%
Close Apr 26 16:00 ET
- 25.410
- 0.0000.00%
Post 16:20 ET
295.65MMarket Cap-6289P/E (TTM)
25.497High25.080Low6.13KVolume25.080Open25.360Pre Close155.12KTurnover0.08%Turnover RatioLossP/E (Static)11.64MShares27.00052wk High3.33P/B202.23MFloat Cap13.48052wk Low--Dividend TTM7.96MShs Float5324.997Historical High--Div YieldTTM1.65%Amplitude3.960Historical Low25.317Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Xoma Earns $9M As FDA Grants Accelerated Approval To Day One's Ojemda (Tovorafenib) For Relapsed Or Refractory BRAF-Altered Pediatric Low-grade Glioma
Express News | XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s Ojemdatm (Tovorafenib) for Relapsed or Refractory Braf-Altered Pediatric Low-Grade Glioma (Plgg)
Express News | HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $74 Price Target
XOMA Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 188.61% HC Wainwright & Co. → $74 Reiterates Buy → Buy 03/11/2024 188.61% HC Wainwright & Co. $
AnaptysBio Names Thomas Smart as CEO >ANAB
AnaptysBio Names Thomas Smart as CEO >ANAB
Express News | Actym Therapeutics Appoints Thomas Smart as CEO
Comments
Biotech Stock News 3/20
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
Biotech Stock News 01/12 @ Open 🛎️📰
$Dyne Therapeutics(DYN.US$ 4% Closing of public offering
$Geron(GERN.US$ 4% Participate @ B. Riley Sec. Conf. '24
$ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS(ZEAL.US$ 2% Capital increase
$XOMA Corp(XOMA.US$ 1% Arimoclomol NDA filing accepted
$Cellectar BioSciences(CLRB.US$ 1% Topline results @ conf. call
$CytomX(CTMX.US$ 0% Present @ B. Riley Sec. Conf. '24
$Dyne Therapeutics(DYN.US$ 4% Closing of public offering
$Geron(GERN.US$ 4% Participate @ B. Riley Sec. Conf. '24
$ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS(ZEAL.US$ 2% Capital increase
$XOMA Corp(XOMA.US$ 1% Arimoclomol NDA filing accepted
$Cellectar BioSciences(CLRB.US$ 1% Topline results @ conf. call
$CytomX(CTMX.US$ 0% Present @ B. Riley Sec. Conf. '24
2
The FDA's acceptance of the NDA is a positive step for XOMA, triggering a milestone payment and bringing the drug closer to potential approval and commercialization. This could lead to future milestone and royalty payments for XOMA, depending on arimoclomol's commercial success.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
diamonds : 请问，ENDPQ重组后，持有的股票还能有效吗？